Monogram Applied sciences mentioned its applied sciences mix 3D printing, superior machine imaginative and prescient, AI, and next-generation robotics. | Supply: Monogram Applied sciences
Zimmer Biomet Holdings, Inc. at this time introduced that it’s buying Monogram Applied sciences Inc., an orthopedic robotics firm. The worldwide medical know-how developer will purchase all excellent shares of Monogram for $4.04 a share, totaling an fairness worth of $177 million and an enterprise worth of $168 million.
“Monogram’s know-how is a serious leap ahead, demonstrating our dedication to turning into the boldest and broadest innovator in surgical robotics and navigation,” mentioned Ivan Tornos, the chairman, president, and CEO of Zimmer Biomet. “Upon closing, our customer-centric portfolio will encompass probably the most complete and versatile know-how ecosystem to help the various preferences of an enormous array of surgeons — now and into the longer term.”
“With Monogram’s proprietary know-how, Zimmer Biomet has the potential to change into the primary firm to ship absolutely autonomous capabilities and redefine each the usual of care and the way forward for orthopedic surgical procedure,” he continued.
The respective boards of administrators of Zimmer Biomet and Monogram unanimously authorised the proposed transaction. Zimmer Biomet, which has places of work in Montpelier, France, and Warsaw, Ind., provides its flagship ROSA platform. ROSA, which not too long ago expanded into shoulder substitute, has 4 functions, together with the knee.
Zimmer Biomet to include Monogram tech into ROSA
Zimmer Biomet mentioned it expects Monogram Applied sciences’ semi- and absolutely autonomous robotic applied sciences so as to add new and differentiated capabilities to broaden its personal surgical robotic.
Monogram has developed a CT-based, semi-autonomous, AI-navigated whole knee arthroplasty (TKA) robotic know-how. It earned FDA 510(okay) clearance in March 2025. The Austin, Texas-based firm mentioned it expects to commercialize the mBôs know-how with Zimmer Biomet implants in early 2027.
As well as, Monogram is creating a completely autonomous model of the mBôs system. It asserted that the know-how might considerably enhance security, effectivity, and outcomes, in addition to deal with functions past TKA.
“Since our inception, we now have been singularly centered on advancing orthopedic robotics with know-how designed to soundly, effectively, and precisely help surgeons with whole knee arthroplasty,” mentioned Benjamin Sexson, CEO of Monogram. “We’re thrilled by the chance so as to add our know-how to Zimmer Biomet’s main portfolio of surgical robotics, navigation options, and trusted implants and to profit from their deep business experience and international scale.”
Zimmer Biomet mentioned it expects the acquisition to contribute to income development in 2027 and past. The firm famous that mBôs will help robotic knee adoption within the U.S., enhance its market share with a broader product vary, and broaden its international knee choices.
Zimmer Biomet to broaden ROSA functions
The proposed transaction expands Zimmer Biomet’s intensive suite of orthopedic robotics. This offers it entry to methods and analytics to handle the wants of surgeons pre-, intra-, and post-operatively. The corporate mentioned its portfolio consists of:
- Imageless robotics by means of its ROSA platform
- A licensed CT-based handheld robotic
- Combined actuality navigation
- AI-based surgical navigation
- A pathway to superior semi- and absolutely autonomous robotics capabilities.
Zimmer Biomet predicted that it will likely be capable of deal with the varied preferences of surgeons globally and a number of kinds of surgical strategies. This consists of CT and non-CT, robotic and non-robotic, and guide, surgeon-centered strategies, or semi- or absolutely autonomous applied sciences.
The ROSA platform is quickly approaching 2,000 installations worldwide, the corporate claimed. Zimmer Biomet mentioned it’s dedicated to persevering with to advance the ROSA platform and is investing in a sturdy R&D pipeline that includes a number of new merchandise and software program functions anticipated between now and 2027.
This consists of ROSA Knee with OptimiZe, which has been submitted to the FDA, and 510(okay) clearance is anticipated later this yr, in addition to ROSA Posterior Hip and the complete business launch of ROSA Shoulder. Zimmer Biomet has additionally labored with THINK Surgical Inc. on integrating the Persona system with the TMINI surgical robotic.
